Daniel Bach

IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team. The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independence IIIM works toward exits through trade sales, mergers or IPOs.

Engages in the development of new medicines based on antibody fragment technology

IP Group invests in companies located in the United Kingdom, United States and Australia. The firm targets companies operating in the fileds of life sciences, deeptech and cleantech. It provides financing for early stage capital requirements.

Operates as a biopharmaceutical company that develops small molecule mitophagy inducers to treat age-related and chronic diseases

Provides biotechnological research and development services

Operates as a clinical-stage oncology company that engages in development of tumor gene therapies

Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye

Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.

Index Ventures invests companies across the globe. The firm target companies operating across a broad range of sectors and industries. It provides financing for seed, early and growth stage capital requirements.